Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference

Rhea-AI Summary

Icosavax, Inc. will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference. The CEO will participate in a fireside chat and interested parties can access the live webcast on the company's website.

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5^th Annual Inflammation, Neurology & Immunology (INI) Conference, taking place from November 6-7, 2023 in New York City.

Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference

• Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in New York on Tuesday, November 7 at 10:30 am ET.
  

Interested parties can register for and access the live webcast for this conference by visiting the “Events” section of the Icosavax website. The webcast replay will be available after the conclusion of the presentation.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

For more information, visit www.icosavax.com.

Media Contact:
Jessica Yingling, Ph.D.,
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091

Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Icosavax, Inc.

What is the focus of Icosavax, Inc.?

Icosavax, Inc. is a biopharmaceutical company focused on developing vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.

What is the vision of Icosavax, Inc.?

The vision of Icosavax, Inc. is to create pan-respiratory vaccines for older adults.

What conference will Icosavax, Inc. participate in?

Icosavax, Inc. will participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference.

Who will participate in a fireside chat at the conference?

Adam Simpson, the Chief Executive Officer of Icosavax, Inc., will participate in a fireside chat at the conference.

When will the fireside chat take place?

The fireside chat will take place on Tuesday, November 7 at 10:30 am ET.

How can interested parties access the live webcast?

Interested parties can register for and access the live webcast on the Icosavax website.

Will there be a webcast replay available?

Yes, the webcast replay will be available after the conclusion of the presentation.